Wuxi Biologics Cayman Inc. revenue for the last year amounted to 2.40 B USD, the most of which — 2.14 B USD — came from its highest performing source at the moment, Biologics, the year earlier bringing 330.58 M USD. The greatest contribution to the revenue figure was made by North America — last year it brought Wuxi Biologics Cayman Inc. 1.14 B USD, and the year before that — 1.26 B USD.